• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[紫杉醇微乳剂的过敏反应及药代动力学研究]

[Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion].

作者信息

He Lei, Wang Gui-ling, Zhang Qiang

机构信息

Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China.

出版信息

Yao Xue Xue Bao. 2003 Mar;38(3):227-30.

PMID:12830723
Abstract

AIM

To evaluate the hypersensitivity reaction of the blank paclitaxel microemulsion and study the O/W paclitaxel microemulsion's pharmacokinetics in rats.

METHODS

An alternative paclitaxel microemulsion was prepared with small particle size. The hypersensitivity reaction of the blank microemulsion was investigated in guinea pigs. In pharmacokinetic study, 5 rats were given i.v. Taxol or paclitaxel microemulsion. Blood samples were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 14 h and the concentration of paclitaxel in plasma was determined by HPLC method. The data obtained were processed using 3P87 program.

RESULTS

The mean size of the microemulsion is 17.2 nm. The preparation of blank microemulsion did not show any hypersensitivity, while the injection of commercial product showed significant hypersensitivity. The concentration-time curve of paclitaxel microemulsion and commercial injection (Taxol) fitted a two-compartment model. The K10, K12, K21 and AUC of paclitaxel microemulsion were 0.571.h-1, 1.441.h-1, 3.081.h-1 and 34.98 mg.h.L-1. Those of commercial injection were 1.291.h-1, 1.271.h-1, 0.511.h-1 and 21.85 mg.h.L-1.

CONCLUSION

The blank paclitaxel preparation of micoemulsion reduced the hypersensitivity in guinea pigs compared with the blank commercial injection. The paclitaxel microemulsion has relatively longer circulating time in rats.

摘要

目的

评价空白紫杉醇微乳的过敏反应,并研究水包油型紫杉醇微乳在大鼠体内的药代动力学。

方法

制备粒径较小的替代型紫杉醇微乳。在豚鼠中研究空白微乳的过敏反应。在药代动力学研究中,给5只大鼠静脉注射紫杉醇或紫杉醇微乳。于0、0.25、0.5、1、2、4、6、8、10、12、14小时采集血样,采用高效液相色谱法测定血浆中紫杉醇浓度。所得数据用3P87程序处理。

结果

微乳平均粒径为17.2nm。空白微乳制剂未显示任何过敏反应,而注射市售产品则显示出明显的过敏反应。紫杉醇微乳和市售注射液(紫杉醇)的浓度 - 时间曲线符合二室模型。紫杉醇微乳的K10、K12、K21和AUC分别为0.571.h-1、1.441.h-1、3.081.h-1和34.98mg.h.L-1。市售注射液的分别为1.291.h-1、1.271.h-1、0.511.h-1和21.85mg.h.L-1。

结论

与空白市售注射液相比,空白紫杉醇微乳制剂降低了豚鼠的过敏反应。紫杉醇微乳在大鼠体内具有相对较长的循环时间。

相似文献

1
[Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion].[紫杉醇微乳剂的过敏反应及药代动力学研究]
Yao Xue Xue Bao. 2003 Mar;38(3):227-30.
2
An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation.一种替代的紫杉醇自乳化微乳制剂:制备、药代动力学特征及超敏反应评估。
PDA J Pharm Sci Technol. 2006 Mar-Apr;60(2):89-94.
3
An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile.一种替代的紫杉醇微乳制剂:超敏反应评估及药代动力学特征
Int J Pharm. 2003 Jan 2;250(1):45-50. doi: 10.1016/s0378-5173(02)00478-7.
4
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.紫杉醇的临床药代动力学和药效学:3小时输注与24小时输注对比
Clin Cancer Res. 1995 Jun;1(6):599-606.
5
Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.水飞蓟素及其制剂对紫杉醇在大鼠体内口服生物利用度的影响。
Eur J Pharm Sci. 2012 Feb 14;45(3):296-301. doi: 10.1016/j.ejps.2011.11.021. Epub 2011 Dec 8.
6
Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics.紫杉醇的无聚氧乙烯蓖麻油静脉微乳剂II.稳定性、体外释放及药代动力学
Int J Pharm. 2008 Feb 12;349(1-2):117-23. doi: 10.1016/j.ijpharm.2007.07.043. Epub 2007 Aug 7.
7
Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies.紫杉醇口服微乳剂:原位及药代动力学研究
Eur J Pharm Biopharm. 2009 Feb;71(2):310-7. doi: 10.1016/j.ejpb.2008.08.015. Epub 2008 Aug 29.
8
Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration.紫杉醇聚乙二醇固体脂质纳米粒经静脉给药后的药代动力学和生物分布。
Arch Pharm Res. 2011 Feb;34(2):331-7. doi: 10.1007/s12272-011-0220-2. Epub 2011 Mar 6.
9
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Cancer Chemother Pharmacol. 2007 Jan;59(1):43-50. doi: 10.1007/s00280-006-0245-2. Epub 2006 May 6.
10
Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?
Biopharm Drug Dispos. 2006 May;27(4):191-6. doi: 10.1002/bdd.503.